Management of patients with amyotrophic lateral sclerosis

Sophie Pautex, Jean-Paul Janssens, Hubert Vuagnat, Pierre Conne, Gilbert B. Zulian

CESCO, Department of Rehabilitation and Geriatrics, University Hospital Geneva, Collonge-Bellerive, Switzerland
Centre Anti-Tuberculeux, University Hospital Geneva, Hôpital Cantonal, Genève, Switzerland
Département Medical de Loex, University Hospital Geneva, Bernex, Switzerland

Standard recommendations for the clinical management of patient with ALS have been edited in recent years. These documents emphasise the importance of patient’s autonomy.

Aim of study: To measure how these different recommendations can be applied in the context of a general hospital without a specific ALS clinic.


Results: Patients suffered from distressing symptoms during their last hospitalisation. Artificial nutrition was given to 5 patients. Six patients had non invasive ventilation (NIV). Written advance directives were only available in 2 cases. Discussions about theses issues were also conducted late in the evolution of the disease.

Conclusion: Some discrepancies between our daily practice and the existing recommendations exist, particularly regarding the key issues of artificial nutrition and ventilatory support.

Key words: amyotrophic lateral sclerosis; palliative care; advance care planning

Introduction

Amyotrophic lateral sclerosis is the most common degenerative motor neuron disorder occurring in adult life. It’s prevalence has been estimated at 6–8/105, with an incidence of 2/105 per year [1]. To date, no curative treatment exists for ALS and symptomatic care must be provided ab initio [2–4]. Recommendations for the clinical management of patients with ALS and their families have been reviewed in recent years by a subcommittee of the American Academy of Neurology (AAN ALS practice parameters) [5].

The aim of the study was to better characterise the end-of-life of patients with ALS and to measure how these different recommendations could be applied in the absence of a specific ALS clinic.

Methods

This study is a review of medical records of patients with a diagnosis of ALS hospitalised at the University Hospitals of Geneva, who died during the 1996–2002 period. According to the AAN ALS practice parameters, information concerning the introduction of artificial nutrition or ventilatory support, as well as the completion of advance directives were noted. Main symptoms present during the last hospitalisation, symptom management and circumstances of death were also collected.

Results

Twenty-one (12 women, 9 men) patients were included in the study. Median age of the patients was 64.2 years (58–80). Twenty patients lived at home and one in a nursing home. Twelve patients were hospitalised at least once in the year before death. Ten patients died in the geriatric ward (4 pa-
patients in a palliative care unit), 6 in the long term care ward, 2 in the acute care ward, 2 at home and 1 in a nursing home. Median length of the last hospitalisation was 42 days. Median length of evolution of ALS from diagnosis until death was 20.8 months (range: 6–60). Reasons for the last admission were general weakness (n = 10), anxiety and/or depression (n = 8), pulmonary infection (n = 3), dysphagia (n = 3) and exacerbation of dyspnoea (n = 2). Comparison of the recommendations of the AAN ALS practice parameters and our finding are listed in table 1.

### Symptom management and palliative care

All patients had some degree of communication impairment and general weakness. Eleven patients had constipation, 8 had insomnia and/or anxiety. Sixteen patients were treated with riluzole until their last days of life; 6 patients received antibiotics for pulmonary infection.

### Nutrition

Although all patients suffered from dysphagia and significant weight loss (>20% of body weight prior to diagnosis), only 5 patients had received a percutaneous endoscopic gastrostomy (PEG), and one patient had parenteral nutrition. Artificial nutrition was introduced 7 months (mean, range: 2–13) before death. Two patients, hospitalised for PEG installation, died during the hospitalisation. Eight patients refused PEG before or during hospitalisation. Nutrition was continued until the last day for all patients with artificial nutrition.

### Table 1

Comparison of AAN ALS practice parameters (left column) and our findings (right column).

<table>
<thead>
<tr>
<th>Breaking the news:</th>
<th>Data not collected in our study</th>
</tr>
</thead>
<tbody>
<tr>
<td>The physician should give the diagnosis to the patient and discuss the implications.</td>
<td>The diagnosis should always be given in person and never by telephone.</td>
</tr>
<tr>
<td>Provide printed materials about the disease and about support and advocacy organisations, and a letter or audiotape summarising what the physician has discussed.</td>
<td>Avoid the following: withholding the diagnosis, providing insufficient information, delivering information callously, or taking away or not providing hope.</td>
</tr>
<tr>
<td>Symptomatic management:</td>
<td></td>
</tr>
<tr>
<td><strong>Salivary</strong></td>
<td>8 patients received glycopyrrolate associated with respiratory therapy.</td>
</tr>
<tr>
<td>Salivary:</td>
<td>No pseudobulbar effect was noted.</td>
</tr>
<tr>
<td>Treat salivary with glycopyrrolate, benztropine, transdermal hyoscine, atropine, trihexyphenidyl hydrochloride, or amitriptyline.</td>
<td>7 patients received antidepressants (SSRI) for depressive mood.</td>
</tr>
<tr>
<td>Treat thick mucus production associated with salivary with propranolol or metoprolol.</td>
<td></td>
</tr>
<tr>
<td>Consider manually assisting coughing and mechanical insufflation-exsufflation for clearing secretions, especially during acute infection.</td>
<td></td>
</tr>
<tr>
<td><strong>Pseudobulbar affect:</strong></td>
<td></td>
</tr>
<tr>
<td>Treat pseudobulbar affect with amitriptyline.</td>
<td></td>
</tr>
<tr>
<td>Consider fluvoxamine as an alternate choice.</td>
<td></td>
</tr>
<tr>
<td><strong>Nutrition:</strong></td>
<td></td>
</tr>
<tr>
<td>PEG is indicated for patients with ALS who have symptomatic dysphagia and should be considered soon after symptom onset.</td>
<td>5 patients had a PEG tube introduced 7 months (mean) before death.</td>
</tr>
<tr>
<td>For optimal safety and efficacy, PEG should be offered and placed when the patient’s VC is more than 50% of predicted.</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory management:</strong></td>
<td></td>
</tr>
<tr>
<td>Be vigilant for symptoms indicating hypoventilation. Offer noninvasive ventilatory support as an effective initial therapy for symptomatic chronic hypoventilation and to prolong survival in patients with ALS.</td>
<td>6 patients were using NIV until their last day of life.</td>
</tr>
<tr>
<td>When long-term survival is the goal, offer invasive ventilation and fully inform patient and family of burdens and benefits.</td>
<td>No invasive ventilation was used.</td>
</tr>
<tr>
<td>In accordance with the principles of patient autonomy, physicians should respect the right of the patient with ALS to refuse or withdraw any treatment, including mechanical ventilation.</td>
<td></td>
</tr>
<tr>
<td>When withdrawing ventilation, use adequate opiates and anxiolytics to relieve dyspnoea and anxiety.</td>
<td></td>
</tr>
<tr>
<td><strong>Palliative care:</strong></td>
<td></td>
</tr>
<tr>
<td>For pain management:</td>
<td>15 patients had pain, 12 received morphine, 1 paracetamol and 1 anti-inflammatory drugs.</td>
</tr>
<tr>
<td>Use non-narcotic analgesics, anti-inflammatory drugs, and antispasticity agents for initial treatment of pain in patients with ALS, and opioids for patients who do not respond to the above.</td>
<td>18 patients received supplemental oxygen and 12 patients received morphine.</td>
</tr>
<tr>
<td>For treating dyspnoea in terminal stages of ALS:</td>
<td></td>
</tr>
<tr>
<td>Use opioids alone or with supplemental oxygen, to treat dyspnoea at rest in patients with ALS, despite the risk of respiratory depression with higher doses.</td>
<td></td>
</tr>
<tr>
<td>For hospice care:</td>
<td>4 patients died in a palliative care unit.</td>
</tr>
<tr>
<td>Consider referral to hospice in the terminal phase of ALS.</td>
<td>5 patients had pain and palliative consultation for advance directives.</td>
</tr>
<tr>
<td>For advance directives:</td>
<td>2 patients had written their advance directives shortly before death.</td>
</tr>
</tbody>
</table>

### Respiration

To alleviate symptoms of chronic hypoventilation, 6 patients had non-invasive ventilation (NIV) with a nasal mask. Median length of NIV was 9.5 months (2–24). For 2 of these patients, NIV was introduced during an emergency hospitalisation for bronchopneumonia. No patient had a tracheotomy. No patient asked to stop NIV before his death. Among the 15 other patients, 3 declined
NIV, 2 patients couldn’t tolerate the mask, one patient had no medical indication for NIV and for one patient NIV was discussed too late in the evolution of the disease.

**Advance directives**

Only two patients had written their advance directives. In both cases this was done during their last hospitalisation, shortly before death.

**Circumstances of death**

Nine patients died of pulmonary infection, 7 patients became comatose and died and 3 patients were found dead in their bed. Three patients with refractory dyspnoea were given terminal sedation with midazolam [6].

**Discussion**

Most of the patients had active symptom management for several distressing symptoms in the last weeks or months of their life, as suggested in the recommendations. Furthermore patients presented with different symptoms that are not addressed in the actual recommendations like communication impairment, general weakness, insomnia, anxiety or constipation [7]. Other questions are not raised in the recommendations such as when to stop riluzole and when to introduce antibiotics. Our results demonstrated some discrepancies between our daily practice and the existing recommendations in the key issues of artificial nutrition and ventilation. These results are similar to Bradley’s study that measured the effect of the AAN ALS practice parameters on the management of ALS. Though the pharmacological symptom management improved significantly, many patients did not receive artificial nutrition or ventilatory support, mainly because lack of patient compliance [8]. In our study, only 6 out of 21 patients (29%) had a PEG performed, which is in the lower range of previously reported studies [7, 9, 10]. Different reasons can by hypothesised to explain this low rate. Patients with ALS do not want their life to be prolonged, since it has been suggested that the early use of PEG may prolong survival, even if no randomised trials are available [5, 11–13]. Another reason for refusing artificial nutrition might be that patients want to eat naturally until the end of their life. Finally, this issue may have been discussed with the patients too late in the evolution of the disease, or not discussed at all. Non invasive ventilation (NIV) via a facial or nasal mask is an effective way of alleviating symptoms of chronic hypoventilation and respiratory muscle failure such as daytime sleepiness, dyspnoea, orthopnoea, sleep disruption, morning headaches and cognitive disorders [4]. In spite of this, although 83% of patients had dyspnoea, less than a third of the patients included in our study had NIV. These results are comparable with other studies, suggesting an under-use of ventilatory support in symptomatic patients [7, 9, 10]. Only two patients in the present study were unable to tolerate the mask or could not use the device. In our study NIV was not proposed systematically to all patients because either the discussion about NIV occurred too late in the evolution of the disease or patients did not want their life to be prolonged [14, 15]. No patient had either a tracheostomy or invasive ventilation. As in several other European countries, invasive ventilation via tracheostomy is an option that is actively discouraged in ALS patients in Switzerland [16].

In 1996, in the Canton of Geneva, a specific legislation relative to advanced directives has been implemented [17]. However, only 2 of 21 patients included in our study had written advanced directives, thus, suggesting lack of information among patients and health professionals in our area. In conclusion, even in lack of ALS clinic, we would recommend the implementation of a multidisciplinary consultation for patients with ALS to support the completion of advance directives and early discussion about artificial nutrition and ventilatory support.

**Correspondence:**

Sophie Pautex, MD
CESCO, Dpt of Rehabilitation and Geriatrics
HUG
Ch. De la Savonnière 11
CH-1245 Collonge-Bellerive Switzerland
sophie.pautex@hcuge.ch

**References**

17 Recueil officiel systématique de la législation genevoise. Loi Genevoise. Vol K1.30; art 5.3; 1996.
The many reasons why you should choose SMW to publish your research

*What Swiss Medical Weekly has to offer:*

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

*Editorial Board*

Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich (Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

*International Advisory Committee*

Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

*Guidelines for authors:*
http://www.smw.ch/set_authors.html

---

*Swiss Medical Weekly: Call for papers*

*Official journal of*

- the Swiss Society of Infectious disease
- the Swiss Society of Internal Medicine
- the Swiss Respiratory Society

---

**Impact factor Swiss Medical Weekly**

- Schweiz Med Wochenschr (1871–2000)
- Swiss Med Wkly (continues Schweiz Med Wochenschr from 2001)

<table>
<thead>
<tr>
<th>Year</th>
<th>Impact Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>0.770</td>
</tr>
<tr>
<td>1996</td>
<td>1.162</td>
</tr>
<tr>
<td>1997</td>
<td>1.537</td>
</tr>
</tbody>
</table>

---

*All manuscripts should be sent in electronic form, to:*

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch